Literature DB >> 27521108

Checkmate: kidney injury associated with targeted cancer immunotherapy.

Mark A Perazella1.   

Abstract

Immune checkpoint inhibitors are a class of drugs that utilizes immunotherapy to target various cancers. Included are the anti-CTLA-4 and anti-PD-1 receptor antibodies. By reprogramming the immune system, these agents provide a therapy that destroys cancer cells. However, this approach runs the risk of allowing pathologic autoimmunity and organ injury to develop. Unsurprisingly, immune-related adverse effects are described including pneumonitis, colitis, and various endocrinopathies. Now added to this list is AKI, primarily due to ATIN.
Copyright © 2016 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27521108     DOI： 10.1016/j.kint.2016.05.024

Source DB:  PubMed          Journal:  Kidney Int        ISSN： 0085-2538            Impact factor:   10.612


  13 in total

Review 1.  Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future.

Authors:  Mark A Perazella; Anushree C Shirali
Journal:  J Am Soc Nephrol       Date:  2018-06-29       Impact factor: 10.121

Review 2.  Pharmacology behind Common Drug Nephrotoxicities.

Authors:  Mark A Perazella
Journal:  Clin J Am Soc Nephrol       Date:  2018-04-05       Impact factor: 8.237

3.  Rapid evolution of acute kidney injury after initial infusion of pembrolizumab in a melanoma patient concurrently treated with RAF/MEK inhibitors.

Authors:  Rohit Thummalapalli; Johannes C Melms; James Mier; Benjamin Izar
Journal:  Melanoma Res       Date:  2020-04       Impact factor: 3.199

4.  Renal toxicities associated with pembrolizumab.

Authors:  Hassan Izzedine; Alexis Mathian; Stephane Champiat; Cécile Picard; Christine Mateus; Emilie Routier; Andrea Varga; David Malka; Alexandra Leary; Judith Michels; Jean-Marie Michot; Aurélien Marabelle; Olivier Lambotte; Zahir Amoura; Jean-Charles Soria; Sihem Kaaki; Nathalie Quellard; Jean-Michel Goujon; Isabelle Brocheriou
Journal:  Clin Kidney J       Date:  2018-11-09

5.  Acute kidney injury predicts all-cause mortality in patients with cancer.

Authors:  Eunjeong Kang; Minsu Park; Peong Gang Park; Namyong Park; Younglee Jung; U Kang; Hee Gyung Kang; Dong Ki Kim; Kook-Hwan Oh; Kwon Wook Joo; Yon Su Kim; Hyung-Jin Yoon; Hajeong Lee
Journal:  Cancer Med       Date:  2019-04-09       Impact factor: 4.452

Review 6.  The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma.

Authors:  Tucci Marco; Passarelli Anna; Todisco Annalisa; Mannavola Francesco; Stucci Luigia Stefania; D'Oronzo Stella; Rossini Michele; Taurisano Marco; Gesualdo Loreto; Silvestris Franco
Journal:  Ther Adv Med Oncol       Date:  2019-09-24       Impact factor: 8.168

7.  Ipilimumab-induced renal granulomatous arteritis: a case report.

Authors:  Mathilde Lemoine; Baptiste Dilly; Alexandre Curie; Vivien Hébert; Charlotte Laurent; Mélanie Hanoy; Steven Grangé; Dominique Guerrot; Arnaud François; Dominique Bertrand
Journal:  BMC Nephrol       Date:  2019-10-11       Impact factor: 2.388

8.  Incidence and Prediction of Immune Checkpoint Inhibitor-related Nephrotoxicity.

Authors:  Jonathan D Sorah; Tracy L Rose; Roshni Radhakrishna; Vimal K Derebail; Matthew I Milowsky
Journal:  J Immunother       Date:  2021-04-01       Impact factor: 4.912

Review 9.  Cancer and the kidney: dangereoux liasons or price paid for the progress in medicine?

Authors:  Jolanta Małyszko; Leszek Kozlowski; Klaudia Kozłowska; Maciej Małyszko; Jacek Małyszko
Journal:  Oncotarget       Date:  2017-05-23

Review 10.  Late renal toxicity of treatment for childhood malignancy: risk factors, long-term outcomes, and surveillance.

Authors:  Roderick Skinner
Journal:  Pediatr Nephrol       Date:  2017-04-22       Impact factor: 3.714
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.